TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00641511
Drug: SYN117 (nepicastat)
Normalized name: Népicastat
DrugBank: Nepicastat (DB12979)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 120 mg per day
Study: NCT01547559
Drug: part1:teprenone
DrugBank: Teprenone (DB15955)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Teprenone 50mg tid after meal for Hp negative patients.
Study: NCT01547559
Drug: part1:teprenone
DrugBank: Teprenone (DB15955)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Teprenone 50mg tid after meal for Hp positive patients.
Study: NCT02737891
Drug: Tesofensine/Metoprolol
DrugBank: Metoprolol (DB00264)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tesofensine 0.5 mg + Metoprolol 100 mg
Study: NCT02036151
Drug: xylitol
Normalized name: Xylitol
DrugBank: Xylitol (DB11195)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Mothers in the experimental group were instructed to chew 1 pellet of xylitol gum (Fennobon Oy, Yrittäjäntie, Finneland -gum, 3 times ) for a period of 3 months. control mothers did not receive any medications. All mothers received oral hygiene instructions and restorative treatment when needed. Offspring of both the experimental and control groups did not receive any medication and were followed for at 6,12, 18 and 24 month from initiation of mothers consumption. month
Study: NCT02036151
Drug: fluoride varnish application
Normalized name: Hydrogen fluoride
DrugBank: Hydrogen fluoride (DB11072)
Approvals — FDA: no, EMA: no, PMDA: no
Description: The control group participated in a preventive program under the supervision of the Pediatric Dentistry Department. The program activities consisted of oral hygiene instructions, fluoride varnish application (Duraphat 5% Na F ,Ultradent Products, Utah, USA) and restorative treatment when needed.
Study: NCT01823562
Drug: lyophilized black raspberry confection
DrugBank: Raspberry (DB10636)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given PO
Study: NCT00966914
Drug: Tavocept(BNP7787) in combination with cisplatin and either docetaxel or paclitaxel
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Paclitaxel 200 mg/m2 IV or Docetaxel 75mg/m2 IV every 3 weeks plus Cisplatin 80 mg/m2 IV every 3weeks plus Tavocept(BNP7787) 18.4gm/m2 IV every 3 weeks
Study: NCT00966914
Drug: Placebo in combination with cisplatin and docetaxel or paclitaxel
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Paclitaxel 200 mg/m2 IV or Docetaxel 75mg/m2 IV every 3 weeks plus Cisplatin 80 mg/m2 IV every 3weeks plus Placebo IV every 3 weeks
Study: NCT04355585
Drug: Colchicine Tablets
Normalized name: Colchicine Tablets
DrugBank: Colchicine (DB01394)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 1.8mg of Colchicine given over 1 hour (1.2 mg followed by 0.6 mg 1 hour later)
Study: NCT00288782
Drug: Mirtazapine
Normalized name: Mirtazapine
DrugBank: Mirtazapine (DB00370)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01843660
Drug: Tramadol HCl-Paracetamol
Normalized name: tramadol and paracetamol
DrugBank: Tramadol (DB00193)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Participants will receive 1 to 2 tablets of tramadol HCl-paracetamol orally once daily (each tablet containing tramadol 37.5 milligram \[mg\] and paracetamol 325mg) for up to a total duration of 6 hours. Additional dose may be given based upon the clinical requirement.
Study: NCT02791568
Drug: Ferumoxytol
Normalized name: Ferumoxytol
DrugBank: Ferumoxytol (DB06215)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: A subset of subjects will complete MRI imaging with ferumoxytol as a contrast agent at the 24-28 week visit. A nurse will administer ferumoxytol in a hospital triage with pulse and blood pressure monitoring and fetal heart monitoring. The pharmacy will prepare the infusion and deliver to triage. Subjects will arrive at the obstetric triage unit for ferumoxytol injection three days prior to their scheduled ferumoxytol MRI study. In the triage, the nurse will obtain baseline vital signs and fetal heart rate. The IV Ferumoxytol infusion will be 30 minutes and atients will be monitored at 5 to 15-minute intervals. Three days after the ferumoxytol infusion, at 24-26 weeks gestation, subjects will have blood/urine collected, undergo a 30 minute ultrasound, a 30 minute MRI, an adverse event review, and medical record review. The MRI scanning procedure will be conducted at WIMR and will last approximately 30-60 minutes.
Study: NCT01845194
Drug: Midazolam
Normalized name: Midazolam
DrugBank: Midazolam (DB00683)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Treatment period 1:~0.2 mg Midazolam 3x~Treatment period 2:~1 mg Midazolam once
Study: NCT01845194
Drug: Torsemide
Normalized name: Torsemide
DrugBank: Torasemide (DB00214)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Treatment period 1:~2.5 mg Torsemide 3x~Treatment period 2:~0.25 mg Torsemide once
Study: NCT01845194
Drug: Talinolol
Normalized name: talinolol
DrugBank: Talinolol (DB11770)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment period 1:~50 mg Talinolol 3x~Treatment period 2:~2.5 mg Talinolol once
Study: NCT01845194
Drug: Metoprolol
Normalized name: Metoprolol
DrugBank: Metoprolol (DB00264)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Treatment period 1:~5 mg Metoprolol 3x
Study: NCT00363935
Drug: Dexmedetomidine
Normalized name: Dexmedetomidine
DrugBank: Dexmedetomidine (DB00633)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT02343549
Drug: Bevacizumab
Normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT02343549
Drug: Temozolomide
Normalized name: Temozolomide
DrugBank: Temozolomide (DB00853)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT03372265
Drug: Ropivacaine 0.2%
Normalized name: ROPivacaine 0.2% injectable solution
DrugBank: Ropivacaine (DB00296)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Perineural infusion using a peripheral nerve block catheter and a portable infusion pump.
Study: NCT02888496
Drug: tocilizumab
Normalized name: Tocilizumab
DrugBank: Tocilizumab (DB06273)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 3 monthly IV infusions in PMR patients
Study: NCT00781573
Drug: Clopidogrel
Normalized name: Clopidogrel
DrugBank: Clopidogrel (DB00758)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Clopidogrel, 75 mg QD, for one year
Study: NCT00305461
Drug: Ciclesonide
Normalized name: Ciclesonide
DrugBank: Ciclesonide (DB01410)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Effect of Ciclesonide on Quality of Life
Study: NCT02902484
Drug: Nintedanib
Normalized name: Nintedanib
DrugBank: Nintedanib (DB09079)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Nintedanib Monotherapy Followed by Combination Therapy of Nintedanib and Gemcitabine Plus nab-Paclitaxel
Study: NCT03545971
Drug: Sintilimab
Normalized name: Sintilimab
DrugBank: Sintilimab (DB15765)
Approvals — FDA: no, EMA: no, PMDA: no
Description: PD-1 monoclonal antibody
Study: NCT00079365
Drug: gemcitabine hydrochloride
Normalized name: Gemcitabine Hydrochloride
DrugBank: Gemcitabine (DB00441)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00479739
Drug: Salmeterol/fluticasone propionate or formoterol/budesonide
DrugBank: Fluticasone propionate (DB00588)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT03823339
Drug: Insulin degludec/liraglutide
Normalized name: INSULIN DEGLUDEC/LIRAGLUTIDE
DrugBank: Liraglutide (DB06655)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Patients will be treated with Insulin degludec/liraglutide (Xultophy®) at the treating physician's discretion and independent from the decision to include the patient in the study.
Study: NCT01425580
Drug: liraglutide
Normalized name: Liraglutide
DrugBank: Liraglutide (DB06655)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 1.8 mg s.c. (QD)
Study: NCT01425580
Drug: glimepiride
Normalized name: Glimepiride
DrugBank: Glimepiride (DB00222)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 4 mg p.o. (QD)
Study: NCT01425580
Drug: Metformin
Normalized name: Metformin
DrugBank: Metformin (DB00331)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 500 mg p.o. (BID)
Study: NCT02084251
Drug: PB-119
Normalized name: PB-722
DrugBank: PB-722 (DB18447)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00681356
Drug: 4975 - 5 mg
Normalized name: dronabinol 5 MG
DrugBank: Dronabinol (DB00470)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Direct instillation into the surgical site
Study: NCT01509053
Drug: Aripiprazole (Abilify®) IM Depot Injection
Normalized name: Aripiprazole
DrugBank: Aripiprazole (DB01238)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 400 mg IM depot injection every 26-30 days. Dosage may be adjusted at the investigator's discretion to 300 mg.~Number of injections: 6. Participants have the option of entering the extension phase of the study and continuing with injections every 26-30 days until the drug is either commercially available, or December 2014.
Study: NCT01509053
Drug: Oral aripiprazole
Normalized name: Aripiprazole
DrugBank: Aripiprazole (DB01238)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Oral aripiprazole tablets 10-15 mg/day (up to 30 mg/day).
Study: NCT01481194
Drug: Bortezomib
Normalized name: Bortezomib
DrugBank: Bortezomib (DB00188)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 1.3 mg/m2 IV push on days 2 and 9 of a 21-day cycle
Study: NCT01481194
Drug: Lenalidomide
Normalized name: Lenalidomide
DrugBank: Lenalidomide (DB00480)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 15 mg orally on days 1-14 of a 21-day cycle
Study: NCT01481194
Drug: Dexamethasone
Normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 20 mg orally on days 2, 3, 9, and 10 of a 21-day cycle
Study: NCT02906605
Drug: JNJ-809
Normalized name: JNJ-42847922
DrugBank: Seltorexant (DB14961)
Approvals — FDA: no, EMA: no, PMDA: no
Description: JNJ-809 (1\*10\^9) colony forming units (CFU) given as an infusion.
Study: NCT02906605
Drug: Apalutamide
Normalized name: Apalutamide
DrugBank: Apalutamide (DB11901)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Apalutamide 240 mg orally daily.
Study: NCT00644085
Drug: aspirin
Normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: oral administration of aspirin 100 mg
Study: NCT00002771
Drug: busulfan
Normalized name: Busulfan
DrugBank: Busulfan (DB01008)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00002771
Drug: cytarabine
Normalized name: Cytarabine
DrugBank: Cytarabine (DB00987)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00002771
Drug: hydroxyurea
Normalized name: Hydroxyurea
DrugBank: Hydroxyurea (DB01005)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00002771
Drug: idarubicin
Normalized name: Idarubicin
DrugBank: Idarubicin (DB01177)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00526929
Drug: darbepoetin alfa
Normalized name: Darbepoetin Alfa
DrugBank: Darbepoetin alfa (DB00012)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 10 mcg NESP administered SC every other week 15 mcg NESP administered SC every other week 20 mcg NESP administered SC every other week 30 mcg NESP administered SC every other week 40 mcg NESP administered SC every other week 50 mcg NESP administered SC every other week 60 mcg NESP administered SC every other week 80 mcg NESP administered SC every other week 100 mcg NESP administered SC every other week
Study: NCT00106613
Drug: FK228 (romidepsin)
Normalized name: Romidepsin
DrugBank: Romidepsin (DB06176)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Patients receive 13 mg/m2 of romidepsin (FK228) intravenously over 4 hours on Days 1, 8, and 15 of each 28-day cycle.
Study: NCT01716416
Drug: Pazopanib
Normalized name: Pazopanib
DrugBank: Pazopanib (DB06589)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT01716416
Drug: Cetuximab
Normalized name: Cetuximab
DrugBank: Cetuximab (DB00002)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT00888043
Drug: CNTO 95 and avastin
Normalized name: Avastin
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: STAGE 1 (Dose escalation) Cohort # subjects CNTO 95 Bevacizumab~* 2 3-6 2.5 mg/kg IV Q3 weeks 7.5 mg/kg IV Q3 weeks~* 1 3-6 2.5 mg/kg IV Q3 weeks 15 mg/kg IV Q3 weeks~  1. 3-6 5 mg/kg IV Q3weeks 15 mg/kg IV Q3 weeks~ 2. 3-6 10 mg/kg IV Q3 weeks 15 mg/kg IV Q3 weeks STAGE 2 (Biomarker) Cohort # subjects CNTO 95 Bevacizumab~ 3. 20 Recommended Phase II Dose Recommended Phase II Dose
Study: NCT00187174
Drug: Everolimus
Normalized name: Everolimus
DrugBank: Everolimus (DB01590)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: The drug is given orally in 28 day courses.
Study: NCT01876082
Drug: PAZOPANIB treatment
DrugBank: Pazopanib (DB06589)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Pazopanib~* 800 mg per day~* oral administration~* at least 1 hour before or 2 hours after a meal,~* until disease progression or for 12 months maximum
Study: NCT02636361
Drug: Insulin lispro (Humalog)
Normalized name: Insulin Lispro
DrugBank: Insulin lispro (DB00046)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Administered SC
Study: NCT00612105
Drug: Retigabine
Normalized name: retigabine
DrugBank: Ezogabine (DB04953)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 150mg/day up to 900mg/day
Study: NCT01105767
Drug: Chlorhexidine gluconate
Normalized name: Chlorhexidine Gluconate
DrugBank: Chlorhexidine (DB00878)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Self applied chlorhexidine body wash (4% chlorhexidine gluconate, Hibiclens®, Mӧlnlycke Heath Care, Norcross, Georgia) once a week to wash/cover the body (except the face and genitalia).
Study: NCT01651962
Drug: Terbutaline
Normalized name: Terbutaline
DrugBank: Terbutaline (DB00871)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02840617
Drug: Indocyanine Green (ICG)
Normalized name: Indocyanine Green
DrugBank: Indocyanine green (DB16024)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00796991
Drug: Ipilimumab
Normalized name: Ipilimumab
DrugBank: Ipilimumab (DB06186)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Solution, intravenous, 10mg/kg, every 3 weeks in the induction phase, up to 4 doses in the induction phase, 48 weeks
Study: NCT00796991
Drug: Carboplatin
Normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Solution, intravenous, Area Under the Concentration Time Curve=6, every 3 weeks in the induction phase, up to 8 doses in the induction phase, 48 weeks
Study: NCT00796991
Drug: Paclitaxel
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Solution, intravenous, 175 mg/m2, every 3 weeks in the induction phase, up to 8 doses in the induction phase, 48 weeks
Study: NCT00796991
Drug: Dacarbazine
Normalized name: Dacarbazine
DrugBank: Dacarbazine (DB00851)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Solution, intravenous, 850 mg/m2, every 3 weeks in the induction phase, up to 8 doses in the induction phase, 48 weeks
Study: NCT00294619
Drug: growth hormone
Normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
Approvals — FDA: no, EMA: no, PMDA: no
Description: subcutaneous injection, once-weekly
Study: NCT01411735
Drug: Enalapril
Normalized name: Enalapril
DrugBank: Enalapril (DB00584)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 2.5mg titrated up to 10mg twice daily
Study: NCT00710086
Drug: Hydromorphone
Normalized name: Hydromorphone
DrugBank: Hydromorphone (DB00327)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous administration of hydromorphone 1mg at the patient's request if they felt uterine contraction pain
Study: NCT00228553
Drug: Armodafinil 100 to 250 mg/day
DrugBank: Modafinil (DB00745)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Armodafinil 100-250 mg: once daily in the morning for patients with obstructive sleep apnea/hypopnea syndrome (OSAHS) or narcolepsy, once daily only on nights worked for patients with shift worker sleep disorder (SWSD).
Study: NCT00946985
Drug: paliperidone palmitate
Normalized name: Paliperidone Palmitate
DrugBank: Paliperidone (DB01267)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 50, 75, 100, or 150 mg eq. monthly injection for 2 years
Study: NCT00946985
Drug: oral risperidone
Normalized name: Risperidone
DrugBank: Risperidone (DB00734)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 2, 4, 6, or 8 mg tabs once daily for two years
Study: NCT01775397
Drug: Fidaxomicin
Normalized name: Fidaxomicin
DrugBank: Fidaxomicin (DB08874)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: capsule
Study: NCT01775397
Drug: Vancomycin
Normalized name: Vancomycin
DrugBank: Vancomycin (DB00512)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: capsule
Study: NCT00271505
Drug: Bevacizumab (Avastin)
Normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 15 mg/kg intravenously (IV) every 3 weeks
Study: NCT00271505
Drug: Carboplatin
Normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: AUC 6 IV every 3 weeks
Study: NCT00271505
Drug: Docetaxel
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 75 mg/m2 IV every 3 weeks
Study: NCT01537614
Drug: COLIMYCINE inhalation
Normalized name: Colimycin
DrugBank: Colistin (DB00803)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 2 MILLION UI
Study: NCT01537614
Drug: COLIMYCINE injectable
Normalized name: Colimycin
DrugBank: Colistin (DB00803)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 2 MILLIONS UI
Study: NCT03309176
Drug: Medroxyprogesterone Acetate 10 MG
Normalized name: medroxyprogesterone acetate 10 MG
DrugBank: Medroxyprogesterone acetate (DB00603)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients in the standard arm will receive Medroxyprogesterone Acetate 10mg daily for 10 days prior to the first ovulation induction cycle and in between anovulatory cycles.
Study: NCT00539188
Drug: N-Acetylcysteine
Normalized name: N-acetylcysteine
DrugBank: Acetylcysteine (DB06151)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 3000 mg PO (1200 mg AM, 1800 mg PM), 6 weeks
Study: NCT02356900
Drug: Oxygen
Normalized name: Oxygen
DrugBank: Oxygen (DB09140)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Used in Hyperoxic hyperbaric interval exercise training intervention
Study: NCT00047645
Drug: Interferon-gamma 1b
Normalized name: Interferon Gamma-1B
DrugBank: Interferon gamma-1b (DB00033)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mcg, SQ, 3x per week
Study: NCT00508664
Drug: Cetuximab
Normalized name: Cetuximab
DrugBank: Cetuximab (DB00002)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Day 1 400mg/m2 i.v. than weekly 250 mg/m2 i.v. for 16 weeks
Study: NCT00508664
Drug: Docetaxel
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 75 mg/m2 i.v. day 1 3 times
Study: NCT00508664
Drug: Cisplatin (TP)
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 75 mg/m2 i.v. day 1 3 times
Study: NCT00508664
Drug: 5-Fluorouracil (TPF) (only until Feb 2009)
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Only patients recruited until Feb 2009: 750 mg/m2 i.v. day 1-5, 3 times
Study: NCT04636983
Drug: BV100
Normalized name: Bempedoic Acid
DrugBank: Bempedoic acid (DB11936)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Rifabutin IV
Study: NCT00272025
Drug: Escitalopram
Normalized name: Escitalopram
DrugBank: Escitalopram (DB01175)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 10mg to 20mg tablet daily for 6 weeks
Study: NCT04206072
Drug: D-0316 Capsule
Normalized name: D
DrugBank: Rosomidnar (DB17154)
Approvals — FDA: no, EMA: no, PMDA: no
Description: The initial dose of D-0316 is 75 mg orally once daily (QD) for one cycle, and then increased to 100 mg orally QD in the absence of CTCAE grade ≥ 2 headache or thrombocytopenia during the first cycle, otherwise maintained to 75 mg orally QD until disease progression or meet the discontinuation criteria. A cycle of treatment is defined as 21 days of once daily treatment.~Following objective disease progression according to RECIST 1.1, as per investigator assessment, patients who were confirmed T790M mutation positive may have the option to continuously receive D-0316.
Study: NCT00749047
Drug: Pioglitazone
Normalized name: Pioglitazone
DrugBank: Pioglitazone (DB01132)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 15-45 mg/day
Study: NCT00612807
Drug: As indicated: Sertraline, bupropion, venlafaxine, mirtazepine, nortriptyline, tranylcypromine, lithium augmentation, etc.
DrugBank: Venlafaxine (DB00285)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Study doctor may prescribe antidepressant medication for the treatment of depression. Medications will be prescribed according to empirically supported guidelines outlined in the Duke Somatic Treatment Algorithm for Geriatric Depression (STAGED Approach; Steffens, 2002).~SSRIs (daily dose of at least 20 mg for citalopram, 20 mg for fluoxetine, 100 mg for sertraline, 20 mg for paroxetine)~SNRIs (e.g., venlafaxine)~Bupropion SR (achieve dose of at least 150 mg BID)~Mirtazapine~Tricyclic antidepressants (nortriptyline with drug levels 80-120 ng/dl)~Lithium augmentation~MAOI (daily dose of at least 30 mg tranylcypromine or 45 mg of phenelzine)
Study: NCT02766140
Drug: SHR1020 plus Docetaxel
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: SHR1020 20mg qd 2-21days, Docetaxel 60 mg/m\^2 IV Day1/3weeks
Study: NCT02766140
Drug: Placebo plus Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Placebo matching SHR1020 qd 2-21days, Docetaxel 60 mg/m\^2 IV Day1/3weeks
Study: NCT02027090
Drug: Routine dose icotinib
Normalized name: nicotine Metered Dose Nasal Spray
DrugBank: Icotinib (DB11737)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Icotinib is administered 125 mg three times daily.
Study: NCT02027090
Drug: Higher dose icotinib
Normalized name: nicotine Metered Dose Nasal Spray
DrugBank: Icotinib (DB11737)
Approvals — FDA: no, EMA: no, PMDA: no
Description: After 8-week induction of icotinib with a dose of 125 mg three times daily, icotinib is administered 375 mg three times per day.
Study: NCT01559740
Drug: Bupivacaine
Normalized name: Bupivacaine
DrugBank: Bupivacaine (DB00297)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: This is being used as the local anesthetic for the TAP blocks at either 0.25% or 0.125%. The block will be done once during the procedure.
Study: NCT00947960
Drug: Triheptanoin
Normalized name: Triheptanoin
DrugBank: Triheptanoin (DB11677)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 1-2 grams triheptanoin (drug)/kilogram body weight divided into 4 equal doses per day taken with meals and a snack for 6 months followed by 1-2 grams vegetable oil (placebo)/kilogram body weight divided into 4 equal doses per day taken with meals and a snack for 6 months.
Study: NCT00645437
Drug: Levofloxacin
Normalized name: Levofloxacin
DrugBank: Levofloxacin (DB01137)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00932828
Drug: Peanut oral immunotherapy
DrugBank: Peanut (DB10553)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Defatted peanut in flour form to be used as treatment for peanut allergy